Females have more trouble with libido and desire than they do with arousal and orgasm, a low desire medical condition called hypoactive sexual desire disorder that occurs in 10% of all women prior to menopause.
Although male desire is often simultaneous with erection, females need to have their interest piqued before they lubricate and physically desire sex.
This is why Viagra and Cialis are effective for males, but physiologically not designed for female sexuality.
So the ‘Pink Pills’ have to work on a unique pathway that involves the brain, not the vagina, where as Viagra and Cialis stimulate the penis before the brain.
Vylessi is the newest Pink Pill to win FDA approval. The competition is Addyi, which is FDA approved, and a variety of herbal alternatives that have just minimal effectiveness over placebo.
Dr. Trupin was one of the Principal Investigators when the medication was with Palatin Technologies, it’s development as a pre-sex injection medication has been studied by AMAG which is bringing it to market this fall. While this technology may be right for many women the treatment of any active gynecologic, urinary, or hormonal issues may also be part of the cure for hypoactive sexual desire disorder.